CoreCap Advisors’s Entrada Therapeutics TRDA Stock Holding History

CoreCap Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-48	Closed	-$434	–	3233
2025 Q1	$434	Buy	+48	New	+$598	﹤0.01%	2740

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

CoreCap Advisors's TRDA Position: Q2 2025 in Review

CoreCap Advisors sold out of Entrada Therapeutics (TRDA) in Q2 2025, closing a stake of 48 shares — an estimated $434 sold.

CoreCap Advisors first reported a position in TRDA in Q1 2025 and held it in 1 quarter. The position peaked at $434 in Q1 2025. 107 funds tracked by Wall St. Rank hold TRDA as of Q2 2025.

CoreCap Advisors reported no remaining Entrada Therapeutics position as of Q2 2025 after selling out during the quarter.
CoreCap Advisors sold 48 Entrada Therapeutics shares in Q2 2025, an estimated $434.
CoreCap Advisors first reported a position in Entrada Therapeutics in Q1 2025 and held it in 1 quarter.
CoreCap Advisors's Entrada Therapeutics position peaked at $434 in Q1 2025.
107 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.